A detailed history of Rathbones Group PLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Rathbones Group PLC holds 253,107 shares of MXCT stock, worth $870,688. This represents 0.01% of its overall portfolio holdings.

Number of Shares
253,107
Previous 262,741 3.67%
Holding current value
$870,688
Previous $1.03 Million 4.37%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.68 - $5.06 $35,453 - $48,748
-9,634 Reduced 3.67%
253,107 $984,000
Q2 2024

Aug 09, 2024

SELL
$3.63 - $5.0 $73,090 - $100,675
-20,135 Reduced 7.12%
262,741 $1.03 Million
Q1 2024

May 14, 2024

SELL
$3.94 - $5.38 $71,361 - $97,442
-18,112 Reduced 6.02%
282,876 $1.19 Million
Q4 2023

Feb 13, 2024

SELL
$2.6 - $5.24 $7,098 - $14,305
-2,730 Reduced 0.9%
300,988 $1.41 Million
Q3 2023

Nov 13, 2023

SELL
$3.02 - $5.1 $113,561 - $191,775
-37,603 Reduced 11.02%
303,718 $947,000
Q2 2023

Aug 04, 2023

SELL
$3.69 - $5.35 $78,460 - $113,757
-21,263 Reduced 5.86%
341,321 $1.57 Million
Q1 2023

May 12, 2023

SELL
$4.03 - $5.89 $20,166 - $29,473
-5,004 Reduced 1.36%
362,584 $1.79 Million
Q4 2022

Feb 14, 2023

SELL
$4.92 - $7.4 $93,548 - $140,703
-19,014 Reduced 4.92%
367,588 $2.01 Million
Q3 2022

Nov 03, 2022

SELL
$4.52 - $6.51 $48,725 - $70,177
-10,780 Reduced 2.71%
386,602 $2.5 Million
Q2 2022

Aug 12, 2022

SELL
$3.59 - $6.81 $38,718 - $73,445
-10,785 Reduced 2.64%
397,382 $1.83 Million
Q1 2022

May 11, 2022

SELL
$5.26 - $10.84 $104,432 - $215,217
-19,854 Reduced 4.64%
408,167 $2.89 Million
Q4 2021

Feb 10, 2022

SELL
$8.87 - $12.94 $170,898 - $249,314
-19,267 Reduced 4.31%
428,021 $4.38 Million
Q3 2021

Nov 04, 2021

BUY
$12.21 - $17.2 $5.46 Million - $7.69 Million
447,288 New
447,288 $5.43 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $350M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Rathbones Group PLC Portfolio

Follow Rathbones Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.